IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to £118,350 for 2021. Pretax loss narrows to £4.5 million from £8.9 million a year earlier, as operating loss reduces to £3.0 million from £6.6 million. Research and development expenditure is £2.0 million, down from £3.7 million in 2021. Chief Executive Officer Tim McCarthy says: ‘As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market.’

Current stock price: 2.70 pence each, down 6.4% on Thursday in London

12-month change: down 55%

Copyright 2023 Alliance News Ltd. All Rights Reserved.